文献速递甲状腺疾病

在达拉非尼/曲美替尼基础上联合检查点抑制治疗BRAFV600E突变型未分化甲状腺癌

Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAFV600E-Mutated Anaplastic Thyroid Carcinoma.
PubMed 文献 · Thyroid · 2024-02-13

回顾性单中心研究纳入71例BRAFV600E突变型未分化甲状腺癌患者,比较一线达拉非尼联合曲美替尼(DT)与在此基础上联合帕博利珠单抗(DTP)的疗效。DTP组中位总生存期17.0个月,显著长于DT组的9.0个月(p=0.037)。新辅助组中位总生存期最长,为63.0个月。

要点

  • DTP组中位总生存期17.0个月,显著长于DT组的9.0个月(p=0.037)。
  • DTP组中位无进展生存期11.0个月,显著长于DT组的4.0个月(p=0.049)。
  • 新辅助组中位总生存期最长,为63.0个月。

核心结论

  • 在BRAFV600E突变型未分化甲状腺癌中,在达拉非尼/曲美替尼基础上联合帕博利珠单抗可能显著延长生存。
  • 对部分患者,初始BRAF靶向治疗后手术切除原发肿瘤可能提供进一步生存获益。
  • 结论受研究回顾性性质的限制,需要额外的前瞻性数据来确认这一观察。

研究设计与样本

  • 回顾性单中心研究,纳入2014年1月至2023年3月间接受一线BRAF靶向治疗的BRAFV600E突变型未分化甲状腺癌患者。
  • 主要分析纳入71例患者:DT组23例,DTP组48例。
  • 评估三组:DT组、DTP组(帕博利珠单抗 upfront 或进展时加入)、新辅助组(手术前DT,手术前后加入帕博利珠单抗),新辅助组为探索性分析,共23例。

主要发现

  • DT组与DTP组基线特征相似,包括治疗开始时存在转移性疾病(p=0.427)、既往手术(p=0.864)和放疗(p=0.678)。
  • DTP组中位总生存期为17.0个月(置信区间CI,11.9-22.1),DT组为9.0个月(CI,4.5-13.5),p=0.037。
  • DTP组中位无进展生存期为11.0个月(CI,7.0-15.0),DT组为4.0个月(CI,0.7-7.3),p=0.049。
  • 探索性新辅助组中位总生存期最长,为63.0个月(CI,15.5-110.5)。
  • 三组均未发生5级不良事件,32.4%的患者发生免疫相关不良事件,最常见为肝炎和结肠炎。

临床怎么用

  • 作者认为,在BRAFV600E突变型未分化甲状腺癌中,在达拉非尼/曲美替尼基础上联合帕博利珠单抗可能显著延长生存。
  • 作者认为,对部分患者,初始BRAF靶向治疗后手术切除原发肿瘤可能提供进一步生存获益。

局限性

  • 结论受研究回顾性性质的限制。
  • 需要额外的前瞻性数据来确认这一观察。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: The dabrafenib plus trametinib combination (DT) has revolutionized the treatment of BRAFV600E-mutated anaplastic thyroid carcinoma (BRAFm-ATC). However, patients eventually develop resistance and progress. Single-agent anti-PD-1 inhibitor spartalizumab has shown a median overall survival (mOS) of 5.9 months. Combination of immunotherapy with BRAF/MEK inhibitors (BRAF/MEKi) seems to improve outcomes compared with BRAF/MEKi alone, although no direct comparison is available. BRAF-targeted therapy before surgery (neoadjuvant approach) has also shown improvement in survival. We studied the efficacy and safety of DT plus pembrolizumab (DTP) compared with current standard-of-care DT alone as an initial treatment, as well as in the neoadjuvant setting. Methods: Retrospective single-center study of patients with BRAFm-ATC treated with first-line BRAF-directed therapy between January 2014 and March 2023. Three groups were evaluated: DT, DTP (pembrolizumab added upfront or at progression), and neoadjuvant (DT before surgery, and pembrolizumab added before or after surgery). The primary endpoint was mOS between DT and DTP. Secondary endpoints included median progression-free survival (mPFS) and response rate with DT versus DTP as initial treatments, and the exploratory endpoint was mOS in the neoadjuvant group. Results: Seventy-one patients were included in the primary analysis: n = 23 in DT and n = 48 in DTP. Baseline demographics were similar between groups, including the presence of metastatic disease at start of treatment (p = 0.427) and prior treatments with surgery (p = 0.864) and radiation (p = 0.678). mOS was significantly longer with DTP (17.0 months [confidence interval CI, 11.9-22.1]) compared with DT alone (9.0 months [CI, 4.5-13.5]), p = 0.037. mPFS was also significantly improved with DTP as the initial treatment (11.0 months [CI, 7.0-15.0]) compared with DT alone (4.0 months [CI, 0.7-7.3]), p = 0.049. Twenty-three patients were in the exploratory neoadjuvant group, where mOS was the longest (63.0 months [CI, 15.5-110.5]). No grade 5 adverse events (AEs) occurred in all three cohorts, and 32.4% had immune-related AEs, most frequently hepatitis and colitis. Conclusions: Our results show that in BRAFm-ATC, addition of pembrolizumab to dabrafenib/trametinib may significantly prolong survival. Surgical resection of the primary tumor after initial BRAF-targeted therapy in selected patients may provide further survival benefit. However, conclusions are limited by the retrospective nature of the study. Additional prospective data are needed to confirm this observation.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Hamidi S, Iyer PC, Dadu R, et al. Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAFV600E-Mutated Anaplastic Thyroid Carcinoma. Thyroid. 2024. PMID: 38226606. doi:10.1089/thy.2023.0573

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。